611 related articles for article (PubMed ID: 18606547)
1. Amiloride is neuroprotective in an MPTP model of Parkinson's disease.
Arias RL; Sung ML; Vasylyev D; Zhang MY; Albinson K; Kubek K; Kagan N; Beyer C; Lin Q; Dwyer JM; Zaleska MM; Bowlby MR; Dunlop J; Monaghan M
Neurobiol Dis; 2008 Sep; 31(3):334-41. PubMed ID: 18606547
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotection in Parkinson models varies with toxin administration protocol.
Anderson DW; Bradbury KA; Schneider JS
Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease.
Schmidt N; Ferger B
Synapse; 2001 Apr; 40(1):47-54. PubMed ID: 11170221
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice.
Callier S; Morissette M; Grandbois M; Pélaprat D; Di Paolo T
Synapse; 2001 Aug; 41(2):131-8. PubMed ID: 11400179
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease.
Liu LX; Chen WF; Xie JX; Wong MS
Neurosci Res; 2008 Feb; 60(2):156-61. PubMed ID: 18054104
[TBL] [Abstract][Full Text] [Related]
6. Oestrogens prevent loss of dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) in substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice.
Jourdain S; Morissette M; Morin N; Di Paolo T
J Neuroendocrinol; 2005 Aug; 17(8):509-17. PubMed ID: 16011487
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
Shin JY; Park HJ; Ahn YH; Lee PH
J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
[TBL] [Abstract][Full Text] [Related]
8. Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism.
Anderson DW; Bradbury KA; Schneider JS
Eur J Neurosci; 2008 Aug; 28(3):610-7. PubMed ID: 18702732
[TBL] [Abstract][Full Text] [Related]
9. Effect of MPTP-induced denervation on basal ganglia GABA(B) receptors: correlation with dopamine concentrations and dopamine transporter.
Calon F; Lavertu N; Lemieux AM; Morissette M; Goulet M; Grondin R; Blanchet PJ; Bédard PJ; Di Paolo T
Synapse; 2001 Jun; 40(3):225-34. PubMed ID: 11304760
[TBL] [Abstract][Full Text] [Related]
10. Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson's disease.
Meuer K; Pitzer C; Teismann P; Krüger C; Göricke B; Laage R; Lingor P; Peters K; Schlachetzki JC; Kobayashi K; Dietz GP; Weber D; Ferger B; Schäbitz WR; Bach A; Schulz JB; Bähr M; Schneider A; Weishaupt JH
J Neurochem; 2006 May; 97(3):675-86. PubMed ID: 16573658
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotective effect of arundic acid, an astrocyte-modulating agent, in mouse brain against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity.
Himeda T; Kadoguchi N; Kamiyama Y; Kato H; Maegawa H; Araki T
Neuropharmacology; 2006 Mar; 50(3):329-44. PubMed ID: 16303147
[TBL] [Abstract][Full Text] [Related]
12. Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons.
Porritt MJ; Batchelor PE; Howells DW
Exp Neurol; 2005 Mar; 192(1):226-34. PubMed ID: 15698637
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine hydroxylase and dopamine transporter expression following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of the mouse nigrostriatal pathway.
Jakowec MW; Nixon K; Hogg E; McNeill T; Petzinger GM
J Neurosci Res; 2004 May; 76(4):539-50. PubMed ID: 15114626
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease.
Watanabe Y; Himeda T; Araki T
Med Sci Monit; 2005 Jan; 11(1):RA17-23. PubMed ID: 15614202
[TBL] [Abstract][Full Text] [Related]
15. Effect of caffeine on the expression of cytochrome P450 1A2, adenosine A2A receptor and dopamine transporter in control and 1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine treated mouse striatum.
Singh S; Singh K; Gupta SP; Patel DK; Singh VK; Singh RK; Singh MP
Brain Res; 2009 Aug; 1283():115-26. PubMed ID: 19520064
[TBL] [Abstract][Full Text] [Related]
16. Estrogen receptors and gonadal steroids in vulnerability and protection of dopamine neurons in a mouse model of Parkinson's disease.
Al-Sweidi S; Morissette M; Bourque M; Di Paolo T
Neuropharmacology; 2011 Sep; 61(4):583-91. PubMed ID: 21586296
[TBL] [Abstract][Full Text] [Related]
17. Toki-to protects dopaminergic neurons in the substantia nigra from neurotoxicity of MPTP in mice.
Sakai R; Irie Y; Murata T; Ishige A; Anjiki N; Watanabe K
Phytother Res; 2007 Sep; 21(9):868-73. PubMed ID: 17486689
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase.
Zhang W; Wang T; Qin L; Gao HM; Wilson B; Ali SF; Zhang W; Hong JS; Liu B
FASEB J; 2004 Mar; 18(3):589-91. PubMed ID: 14734632
[TBL] [Abstract][Full Text] [Related]
19. Alteration of dopaminergic markers in gastrointestinal tract of different rodent models of Parkinson's disease.
Tian YM; Chen X; Luo DZ; Zhang XH; Xue H; Zheng LF; Yang N; Wang XM; Zhu JX
Neuroscience; 2008 May; 153(3):634-44. PubMed ID: 18420351
[TBL] [Abstract][Full Text] [Related]
20. Exploring the neuroprotective effects of modafinil in a marmoset Parkinson model with immunohistochemistry, magnetic resonance imaging and spectroscopy.
van Vliet SA; Blezer EL; Jongsma MJ; Vanwersch RA; Olivier B; Philippens IH
Brain Res; 2008 Jan; 1189():219-28. PubMed ID: 18076869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
